An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
NCT05929716 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it was withdrawn. It studies CAR T leukapheresis, Magrolimab, Radiation and Rituximab in B-cell Lymphoma and Large B-cell Lymphoma. The registry lists an enrollment of 0 participants. The registry lists a start date of 30 Sept 2023 and a primary completion date of 1 Mar 2026.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05929716 |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | M.D. Anderson Cancer Center |
| Enrollment | 0 |
| Conditions | B-cell Lymphoma and Large B-cell Lymphoma |
| Drugs | CAR T leukapheresis, Magrolimab, Radiation and Rituximab |
| Start | 30 Sept 2023 |
| Primary completion | 1 Mar 2026 |
| Study completion | 1 Mar 2028 |
| Last update posted | 13 Nov 2023 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Paolo Strati, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05929716
Each answer restates registry values shown on this page.
What is NCT05929716?
NCT05929716 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies CAR T leukapheresis, Magrolimab, Radiation and Rituximab in B-cell Lymphoma and Large B-cell Lymphoma.
Who leads NCT05929716?
The registry names Paolo Strati, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.
Which drugs does NCT05929716 study?
The registered drug and biological interventions are CAR T leukapheresis, Magrolimab, Radiation and Rituximab.
When did NCT05929716 end?
The registry lists a primary completion date of 1 Mar 2026 and a study completion date of 1 Mar 2028. The sponsor last updated the record on 13 Nov 2023.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.